Literature DB >> 8013100

Rapid automated enzyme immunoassay of serum amyloid A.

J Wilkins1, J R Gallimore, G A Tennent, P N Hawkins, P C Limburg, M H van Rijswijk, E G Moore, M B Pepys.   

Abstract

Serum amyloid A (SAA), a sensitive acute-phase protein, is the precursor of AA fibrils in reactive amyloidosis. However, SAA is poorly immunogenic, and development and standardization of immunoassays of this protein have been difficult. We established an automated polyclonal/monoclonal microparticle capture enzyme immunoassay, standardized with the World Health Organization prospective reference standard for SAA. A stabilized concentrate of SAA was used for controls and calibrators. The assay range was 1-750 mg/L with CVs < 7% throughout. Plasma and serum gave identical results and no interferences were observed. Linear regression against radial immunodiffusion assay gave a slope of 1.04 (95% confidence interval 0.99-1.10), intercept of -9 mg/L (95% confidence interval -14-3), and residual SD (SEE) of 20 for samples containing < or = 200 mg/L (n = 173). In 105 apparently healthy adults the mean (SD) SAA concentration was 3.7 (3.6) mg/L, the median was 3.0 mg/L, and the range, 0.7-26.4 mg/L. In clinical acute-phase sera, values up to 2200 mg/L were seen. This method will facilitate measurement and investigation of SAA in clinical practice generally and in AA amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013100

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  11 in total

1.  Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.

Authors:  Cailin H Sibley; Nikki Plass; Joseph Snow; Edythe A Wiggs; Carmen C Brewer; Kelly A King; Christopher Zalewski; H Jeffrey Kim; Rachel Bishop; Suvimol Hill; Scott M Paul; Patrick Kicker; Zachary Phillips; Joseph G Dolan; Brigitte Widemann; Nalini Jayaprakash; Frank Pucino; Deborah L Stone; Dawn Chapelle; Christopher Snyder; John A Butman; Robert Wesley; Raphaela Goldbach-Mansky
Journal:  Arthritis Rheum       Date:  2012-07

Review 2.  Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities.

Authors:  Curtis J Omiecinski; John P Vanden Heuvel; Gary H Perdew; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2010-11-08       Impact factor: 4.849

3.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; J R Gallimore; M B Pepys
Journal:  BMJ       Date:  2000-07-22

4.  Genome-wide association study identifies two novel regions at 11p15.5-p13 and 1p31 with major impact on acute-phase serum amyloid A.

Authors:  Carola Marzi; Eva Albrecht; Pirro G Hysi; Vasiliki Lagou; Melanie Waldenberger; Anke Tönjes; Inga Prokopenko; Katharina Heim; Hannah Blackburn; Janina S Ried; Marcus E Kleber; Massimo Mangino; Barbara Thorand; Annette Peters; Christopher J Hammond; Harald Grallert; Bernhard O Boehm; Peter Kovacs; Ludwig Geistlinger; Holger Prokisch; Bernhard R Winkelmann; Tim D Spector; H-Erich Wichmann; Michael Stumvoll; Nicole Soranzo; Winfried März; Wolfgang Koenig; Thomas Illig; Christian Gieger
Journal:  PLoS Genet       Date:  2010-11-18       Impact factor: 5.917

5.  Serologic evaluation of clinical and subclinical secondary hepatic amyloidosis in rhesus macaques (Macaca mulatta).

Authors:  Jamus G MacGuire; Kari L Christe; JoAnn L Yee; Alexis L Kalman-Bowlus; Nicholas W Lerche
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

6.  The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.

Authors:  L B Lovat; M R Persey; S Madhoo; M B Pepys; P N Hawkins
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

7.  Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis.

Authors:  M E Perry; Anne Stirling; J A Hunter
Journal:  Clin Rheumatol       Date:  2008-04-01       Impact factor: 2.980

8.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Authors:  Raphaela Goldbach-Mansky; Natalie J Dailey; Scott W Canna; Ana Gelabert; Janet Jones; Benjamin I Rubin; H Jeffrey Kim; Carmen Brewer; Christopher Zalewski; Edythe Wiggs; Suvimol Hill; Maria L Turner; Barbara I Karp; Ivona Aksentijevich; Frank Pucino; Scott R Penzak; Margje H Haverkamp; Leonard Stein; Barbara S Adams; Terry L Moore; Robert C Fuhlbrigge; Bracha Shaham; James N Jarvis; Kathleen O'Neil; Richard K Vehe; Laurie O Beitz; Gregory Gardner; William P Hannan; Robert W Warren; William Horn; Joe L Cole; Scott M Paul; Philip N Hawkins; Tuyet Hang Pham; Christopher Snyder; Robert A Wesley; Steven C Hoffmann; Steven M Holland; John A Butman; Daniel L Kastner
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

Review 9.  Acute phase reactants as novel predictors of cardiovascular disease.

Authors:  M S Ahmed; A B Jadhav; A Hassan; Qing H Meng
Journal:  ISRN Inflamm       Date:  2012-05-06

10.  Low-grade systemic inflammation profile, unrelated to homocysteinemia, in obese children.

Authors:  Emanuel V Economou; Ariadne V Malamitsi-Puchner; Christos P Pitsavos; Evangelia E Kouskouni; Ioanna Magaziotou-Elefsinioti; George Creatsas
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.